The benefits of SGLT2 inhibitors in cardiovascular and renal outcomes have been reported in large outcome studies such as the EMPA-REG OUTCOME trial [143], CANVAS (CANagliflozin cardiovascular Assessment Study) [144], DECLARE–TIMI 58 [145], Comparative Effectiveness of Cardiovascular Outcomes (CVD REAL) real-world study [146], and DAPA-HF trial [147]). The gene discussed is SLC5A2; the disease is hydrops fetalis.